Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 153
Filtrar
Más filtros

Medicinas Complementárias
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Front Endocrinol (Lausanne) ; 15: 1327623, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38362274

RESUMEN

Background: Elderly people are at high risk of falls due to decreased muscle strength. So far, there is currently no officially approved medication for treating muscle strength loss. The active vitamin D analogues are promising but inconsistent results have been reported in previous studies. The present study was to meta-analyze the effect of active vitamin D analogues on muscle strength and falls in elderly people. Methods: The protocol was registered with PROSPERO (record number: CRD42021266978). We searched two databases including PubMed and Cochrane Library up until August 2023. Risk ratio (RR) and standardized mean difference (SMD) with 95% confidence intervals (95% CI) were used to assess the effects of active vitamin D analogues on muscle strength or falls. Results: Regarding the effects of calcitriol (n= 1), alfacalcidol (n= 1) and eldecalcitol (n= 1) on falls, all included randomized controlled trials (RCT) recruited 771 participants. Regarding the effects of the effects of calcitriol (n= 4), alfacalcidol (n= 3) and eldecalcitol (n= 3) on muscle strength, all included RCTs recruited 2431 participants. The results showed that in the pooled analysis of three active vitamin D analogues, active vitamin D analogues reduced the risk of fall by 19%. Due to a lack of sufficient data, no separate subgroup analysis was conducted on the effect of each active vitamin D analogue on falls. In the pooled and separate analysis of active vitamin D analogues, no significant effects were found on global muscle, hand grip, and back extensor strength. However, a significant enhancement of quadriceps strength was observed in the pooled analysis and separate analysis of alfacalcidol and eldecalcitol. The separate subgroup analysis on the impact of calcitriol on the quadriceps strength was not performed due to the lack to sufficient data. The results of pooled and separate subgroup analysis of active vitamin D analogues with or without calcium supplementation showed that calcium supplementation did not affect the effect of vitamin D on muscle strength. Conclusions: The use of active vitamin D analogues does not improve global muscle, hand grip, and back extensor strength but improves quadriceps strength and reduces risk of falls in elderly population.


Asunto(s)
Accidentes por Caídas , Fuerza Muscular , Vitamina D , Humanos , Accidentes por Caídas/prevención & control , Fuerza Muscular/efectos de los fármacos , Anciano , Vitamina D/análogos & derivados , Vitamina D/farmacología , Hidroxicolecalciferoles/uso terapéutico , Hidroxicolecalciferoles/farmacología , Calcitriol/análogos & derivados , Calcitriol/farmacología , Ensayos Clínicos Controlados Aleatorios como Asunto
2.
Horm Mol Biol Clin Investig ; 29(3): 85-91, 2017 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-28157691

RESUMEN

BACKGROUND: The aim of this randomized clinical trial (RCT) was to evaluate the effect of vitamin D supplementation in obese, insulin-resistant (IR) and vitamin D-deficient polycystic ovary syndrome (PCOS) women on metabolic abnormalities in comparison to the effect of metformin or combined metformin plus vitamin D therapy. MATERIAL AND METHODS: Thirty-nine PCOS women who fulfilled the inclusion criteria were randomized into three groups and treated with alfacalcidiol, combined alfacalcidiol and metformin therapy and metformin for 6 months. Body weight, body mass index (BMI), waist circumference, total body fat and fat distribution were measured before and after 6 months of treatment. Plasma fasting glucose, insulin, homeostasis model assessment-insulin resistance (HOMA-IR) and lipid profiles were measured at the same time. RESULTS: There was a significant decrease in body weight, BMI, waist circumference, total body fat and serum glucose levels in the metformin group (p<0.05), whereas PCOS women treated with alfacalcidiol did not significantly change their anthropometric and metabolic parameters. A significant decrease in waist circumference (p<0.05) in the group treated with metformin and alfacalcidiol was detected without other significant metabolic changes (all p>0.05). There were no significant changes in metabolic parameters (p>0.05) after vitamin D therapy except for a slight but non-significant trend towards higher high-density lipoprotein (HDL) cholesterol levels (p=0.087). CONCLUSION: We conclude that vitamin D supplementation has no significant effect on anthropometric and metabolic parameters in PCOS women. Metformin has been still the most effective modality for the treatment of metabolic changes in PCOS.


Asunto(s)
Hidroxicolecalciferoles/farmacología , Resistencia a la Insulina , Metformina/farmacología , Síndrome del Ovario Poliquístico/metabolismo , Vitamina D/administración & dosificación , Adulto , Biomarcadores/análisis , Glucemia/análisis , Índice de Masa Corporal , Conservadores de la Densidad Ósea/farmacología , Femenino , Estudios de Seguimiento , Humanos , Hipoglucemiantes/farmacología , Lípidos/análisis , Masculino , Obesidad/fisiopatología , Síndrome del Ovario Poliquístico/tratamiento farmacológico , Síndrome del Ovario Poliquístico/patología , Vitaminas/administración & dosificación
3.
Sci Rep ; 7: 40370, 2017 01 11.
Artículo en Inglés | MEDLINE | ID: mdl-28074906

RESUMEN

Early detection and surgery represent the mainstay of treatment for superficial melanoma, but for high risk lesions (Breslow's thickness >0.75 mm) an effective adjuvant therapy is lacking. Vitamin D insufficiency plays a relevant role in cancer biology. The biological effects of 1α hydroxycholecalciferol on experimental melanoma models were investigated. 105 melanoma patients were checked for 25-hydroxycholecalciferol (circulating vitamin D) serum levels. Human derived melanoma cell lines and in vivo xenografts were used for studying 1α-hydroxycholecalciferol-mediated biological effects on cell proliferation and tumor growth. 99 out of 105 (94%) melanoma patients had insufficient 25-hydroxycholecalciferol serum levels. Interestingly among the six with vitamin D in the normal range, five had a diagnosis of in situ/microinvasive melanoma. Treatment with 1α-hydroxycholecalciferol induced antiproliferative effects on melanoma cells in vitro and in vivo, modulating the expression of cell cycle key regulatory molecules. Cell cycle arrest in G1 or G2 phase was invariably observed in vitamin D treated melanoma cells. The antiproliferative activity induced by 1α-hydroxycholecalciferol in experimental melanoma models, together with the discovery of insufficient 25-hydroxycholecalciferol serum levels in melanoma patients, provide the rationale for using vitamin D in melanoma adjuvant therapy, alone or in association with other therapeutic options.


Asunto(s)
Hidroxicolecalciferoles/uso terapéutico , Melanoma/tratamiento farmacológico , Melanoma/patología , Adulto , Anciano , Anciano de 80 o más Años , Carcinogénesis/efectos de los fármacos , Carcinogénesis/patología , Ciclo Celular/efectos de los fármacos , Diferenciación Celular/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Forma de la Célula/efectos de los fármacos , Ergocalciferoles/farmacología , Ergocalciferoles/uso terapéutico , Femenino , Humanos , Hidroxicolecalciferoles/administración & dosificación , Hidroxicolecalciferoles/farmacología , Masculino , Melanoma/sangre , Persona de Mediana Edad
4.
Physiol Res ; 65(5): 815-822, 2016 11 23.
Artículo en Inglés | MEDLINE | ID: mdl-27429113

RESUMEN

Aim of this study was to evaluate the effect of vitamin D supplementation in obese, insulin resistant and vitamin D deficient PCOS women on biochemical and clinical hyperandrogenism and menstrual irregularity in comparison to effect of metformin or combined metformin plus vitamin D therapy. Thirty nine PCOS women were randomized into three groups and treated with alfacalcidiol (Group 1), combined alfacalcidiol and metformin therapy (Group 2) and metformin (Group 3) for 6 months. Serum TST, fTST, DHEAS, LH and LH/FSH were measured before and after six months of treatment. Menstrual cycle regularity, hirsutism, acne and pregnancy rate were assessed at the same time. There was a significant decrease in TST levels in the Group 2 and slight but not significant decrease in the Group 3. No significant changes in other parameters (fTST, DHEAS, LH, LH/FSH) have been found after 6 months therapy in all three groups. An improvement of menstrual cycle was detected in 78 % of patients in Group 1 (p<0.04), 80 % in the Group 2 (p<0.03) and in 90 % in the Group 3 (p<0.002), respectively. There was no significant improvement of acne and hirsutism in all three groups (all p not significant). Pregnancy rate was higher in the Group 3 as compared with Groups 1 and 2 (67 % vs. 0 % and 25 %, respectively), however without statistical significance. Vitamin D administration has no significant effect on androgen levels and clinical features of hyperandrogenism in obese vitamin D deficient PCOS women. However, it can potentiate effect of metformin on testosterone levels and LH/FSH ratio but not on clinical hyperandrogenism and pregnancy rate.


Asunto(s)
Hidroxicolecalciferoles/uso terapéutico , Hiperandrogenismo/tratamiento farmacológico , Ciclo Menstrual/efectos de los fármacos , Síndrome del Ovario Poliquístico/tratamiento farmacológico , Adulto , Femenino , Humanos , Hidroxicolecalciferoles/farmacología , Hipoglucemiantes/farmacología , Hipoglucemiantes/uso terapéutico , Resistencia a la Insulina , Metformina/farmacología , Metformina/uso terapéutico , Obesidad/complicaciones , Fenotipo , Proyectos Piloto , Síndrome del Ovario Poliquístico/sangre , Síndrome del Ovario Poliquístico/complicaciones , Embarazo , Índice de Embarazo , Adulto Joven
5.
Am J Ther ; 23(5): e1135-42, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26291589

RESUMEN

Bu-Shen-Jian-Pi-Yi-Qi therapy, which refers to reinforcing kidney, regulating qi, and invigorating spleen, is a traditional Chinese medicine, and we investigated its efficacy in treatment of alcohol-induced osteoporosis and its underlying mechanism. Forty adult male Sprague-Dawley rats were randomly assigned into alcohol-supplemented group, JIAN-GU-LING (JGL) group, calcium D3 + alfacalcidol group, and sham-treated group. Bone mineral density (BMD), bone mineral content (BMC), and bone biomechanical properties were assessed. Biochemical analyses of serum and urine specimens were detected. Reverse transcription-polymerase chain reaction was used to detect the mRNA level of vitamin D receptor (VDR). There were markedly lower bone metabolic markers and biomechanical properties in alcohol-supplemented group compared with sham-treated group (all P < 0.05). BMD, BMC, 25(OH)D3, and 1,25(OH)2D3 were elevated in JGL group relative to calcium D3 + alfacalcidol group (all P < 0.05). U-Ca/Cr and U-P/Cr in JGL group were higher than those in the calcium D3 + alfacalcidol group (all P < 0.05). VDR mRNA level in the JGL group was elevated markedly in comparison with alcohol + calcium D3 + alfacalcidol group (P < 0.05). Based on our results, Bu-Shen-Jian-Pi-Yi-Qi therapy inhibits bone loss, promotes bone formation, and effectively improves bone metabolism in rats with experimental alcoholic osteoporosis. The disease reversal is evidenced by increased BMD and BMC, improved biomechanical properties, elevated VDR mRNA level, enhanced response sensitivity of 1, 25(OH)2D3, and reduced S-Ca/P.


Asunto(s)
Medicamentos Herbarios Chinos/farmacología , Etanol/efectos adversos , Medicina Tradicional China/métodos , Osteoporosis/prevención & control , Animales , Densidad Ósea/efectos de los fármacos , Calcio/administración & dosificación , Colecalciferol/administración & dosificación , Modelos Animales de Enfermedad , Etanol/administración & dosificación , Hidroxicolecalciferoles/farmacología , Masculino , Osteoporosis/etiología , Qi , ARN Mensajero/metabolismo , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley , Receptores de Calcitriol/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa
6.
J Gastroenterol Hepatol ; 30(9): 1384-90, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-25778685

RESUMEN

BACKGROUND AND AIM: An intention-to-treat prospective randomized study was carried out to compare the potentiation of antiviral efficacies between cholecalciferol, non-activated vitamin D3 supplement, and alfacalcidol, activated 1α-Hydroxyvitamin D3 [1α (OH)-vitamin D3]. METHODS: Chronic hepatitis patients with genotype 1b hepatitis C virus (HCV) infection showing serum HCV-RNA levels greater than 5 Log IU/mL received oral administration of cholecalciferol (2000 IU/day) or alfacalcidol (0.5 µg/day) for 4 weeks, and then they were given pegylated interferon (Peg-IFN)-α2a plus ribavirin therapy in combination with either vitamin D3 for 48 or 72 weeks according to the response-guided manner. RESULTS: A total of 36 patients were evaluated. Serum 25-hydroxyvitamin D3 [25(OH)-D3] levels were increased only in patients in the cholecalciferol group during the lead-in vitamin D administration, and the levels at 4 weeks were higher in these patients than in those in the alfacalcidol group (P < 0.001), while serum 1α,25-dihydroxyvitamin D3 [1α,25(OH)2 -D3] levels were not different between both groups. Rapid virological response was obtained in six (33%) patients in the cholecalciferol group; the ratio was higher than that in the alfacalcidol group (one patient; 6%, P < 0.05). Serum HCV-RNA level decline at 4 weeks of combined Peg-IFN-α2a plus ribavirin therapy compared with the baseline levels were greater in the cholecalciferol group (4.6 Log IU/mL) than in the alfacalcidol group (3.5 Log IU/mL) (P < 0.05), when four patients showing null response to the therapy was excluded. However, both complete early virological response and sustained viral response rates were not different between both groups. CONCLUSION: Cholecalciferol produced superior potentiation of the antiviral activity than alfacalcidol only during the initial periods of combined Peg-IFN-α2a plus ribavirin therapy through upregulation of serum 25(OH)-D3 levels.


Asunto(s)
Antivirales/administración & dosificación , Colecalciferol/administración & dosificación , Hepatitis C Crónica/tratamiento farmacológico , Hidroxicolecalciferoles/administración & dosificación , Interferón-alfa/administración & dosificación , Polietilenglicoles/administración & dosificación , Ribavirina/administración & dosificación , Administración Oftálmica , Anciano , Biomarcadores/sangre , Calcifediol/sangre , Colecalciferol/farmacología , Sinergismo Farmacológico , Quimioterapia Combinada , Femenino , Hepacivirus/genética , Hepatitis C Crónica/virología , Humanos , Hidroxicolecalciferoles/farmacología , Masculino , Persona de Mediana Edad , Estudios Prospectivos , ARN Viral/sangre , Proteínas Recombinantes/administración & dosificación , Resultado del Tratamiento , Regulación hacia Arriba/efectos de los fármacos
7.
Eksp Klin Gastroenterol ; (2): 25-31, 2014.
Artículo en Ruso | MEDLINE | ID: mdl-25518471

RESUMEN

Osteoporosis is simulated in rats by chronic administration of omeprazole or serotonin for 6 months; investigated bone status in the model of liver fibrosis and the administration of serotonin against liver fibrosis. The following experimental groups of rats: with bilateral ovariectomy, with bilateral ovariectomy and administration of omeprazole, with the introduction of serotonin, with serotonin administration and bilateral ovariectomy, with model of liver fibrosis, with liver fibrosis model and administration of serotonin were used. The content of Ca, P, alkaline phosphatase, albumin, serum creatinine, and the content of Ca, P, Mg andFe in the bone was determined. It was found that the administration of mesenchymal stromal cells reduces the severity of osteoporosis. The effects of alfacalcidol on experimental osteoporosis was investigated. Introduction of alfacalcidol in all experimental groups increased the bone formation.


Asunto(s)
Conservadores de la Densidad Ósea/farmacología , Hidroxicolecalciferoles/farmacología , Trasplante de Células Madre Mesenquimatosas , Osteogénesis/efectos de los fármacos , Osteoporosis/sangre , Osteoporosis/terapia , Aloinjertos , Animales , Antiulcerosos/efectos adversos , Antiulcerosos/farmacología , Modelos Animales de Enfermedad , Femenino , Cirrosis Hepática/sangre , Cirrosis Hepática/inducido químicamente , Cirrosis Hepática/terapia , Metales/sangre , Omeprazol/efectos adversos , Omeprazol/farmacología , Osteoporosis/etiología , Ovariectomía , Fósforo/sangre , Ratas , Ratas Wistar , Serotonina/efectos adversos , Serotonina/farmacología , Agonistas de Receptores de Serotonina/efectos adversos , Agonistas de Receptores de Serotonina/farmacología
8.
Biopharm Drug Dispos ; 34(7): 402-16, 2013 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-23897575

RESUMEN

Previous studies have shown that 1α,25-dihydroxyvitamin D3 [1,25(OH)2 D3 ] treatment in mice resulted in induction of intestinal and renal Cyp24a1 and Trpv6 expression, increased hepatic Cyp7a1 expression and activity, as well as higher renal Mdr1/P-gp expression. The present study compared the equimolar efficacies of 1α-hydroxyvitamin D3 [1α(OH)D3 ] (6 nmol/kg i.p. q2d × 4), a lipophilic precursor with a longer plasma half-life that is converted to 1,25(OH)2 D3 , and 1,25(OH)2 D3 on vitamin D receptor (VDR) target genes. To clarify whether changes in VDR genes was due to VDR and not secondary, farnesoid X receptor (FXR)-directed effects, namely, lower Cyp7a1 expression in rat liver due to increased bile acid absorption, wildtype [fxr(+/+)] and FXR knockout [fxr(-/-)] mice were used to distinguish between VDR and FXR effects. With the exception that hepatic Sult2a1 mRNA was increased equally well by 1α(OH)D3 and 1,25(OH)2 D3 , 1α(OH)D3 treatment led to higher increases in hepatic Cyp7a1, renal Cyp24a1, VDR, Mdr1 and Mrp4, and intestinal Cyp24a1 and Trpv6 mRNA expression in both fxr(+/+) and fxr(-/-) mice compared to 1,25(OH)2 D3 treatment. A similar induction in protein expression and microsomal activity of hepatic Cyp7a1 and renal P-gp and Mrp4 protein expression was noted for both compounds. A higher intestinal induction of Trpv6 was observed, resulting in greater hypercalcemic effect following 1α(OH)D3 treatment. The higher activity of 1α(OH)D3 was explained by its rapid conversion to 1,25(OH)2 D3 in tissue sites, furnishing higher plasma and tissue 1,25(OH)2 D3 levels compared to following 1,25(OH)2 D3 -treatment. In conclusion, 1α(OH)D3 exerts a greater effect on VDR gene induction than equimolar doses of 1,25(OH)2 D3 in mice.


Asunto(s)
Calcitriol/farmacología , Hidroxicolecalciferoles/farmacología , Receptores de Calcitriol/genética , Receptores Citoplasmáticos y Nucleares/genética , Animales , Calcitriol/sangre , Calcitriol/farmacocinética , Calcio/sangre , Sistema Enzimático del Citocromo P-450/genética , Sistema Enzimático del Citocromo P-450/metabolismo , Hidroxicolecalciferoles/farmacocinética , Íleon/efectos de los fármacos , Íleon/metabolismo , Riñón/efectos de los fármacos , Riñón/metabolismo , Hígado/efectos de los fármacos , Hígado/metabolismo , Proteínas de Transporte de Membrana/genética , Ratones , Ratones Noqueados , Fósforo/sangre , Sulfotransferasas/genética
9.
J Bone Miner Metab ; 30(3): 349-58, 2012 May.
Artículo en Inglés | MEDLINE | ID: mdl-22130786

RESUMEN

Vitamin D insufficiency is prevalent in osteopenic and osteoporotic postmenopausal women. The persistent increase in circulating parathyroid hormone (PTH) caused by vitamin D insufficiency reduces bone density response to antiresorptive agents in these postmenopausal women. It is not well known whether administration of raloxifene might increase serum PTH secondary to the suppression of serum calcium in postmenopausal women with osteopenia or osteoporosis. We tried to assess whether raloxifene might affect serum PTH and whether the addition of alfacalcidol to raloxifene therapy could have favorable effects on bone mineral density (BMD) and bone turnover as compared to raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia (≤2.0 SD based on young Japanese women). A total of 169 subjects were randomly assigned to groups receiving 60 mg raloxifene (R), or 1 µg alfacalcidol (D), or a combination of both (R + D) for 2 years. Serum levels of 25-hydroxyvitamin D [25(OH)D] were measured at randomization. The modified 'intention to treat' method was used. We compared the groups using a Tukey-Kramer test for changes in L- and TH-BMD and calcium metabolism when significant differences were found using one-way ANOVA. The parameters in each group during the experimental period were analyzed by means of paired t tests. Baseline 25(OH)D and i-PTH were 23.7 ng/ml and 38.4 pg/ml, respectively. At 6 months, i-PTH demonstrated a significant increase (+21.0%) in the R-group whereas significant decreases in i-PTH were observed in the D-group and combination-group (-15.9 and -8.9%, respectively). There were significant increases in L-BMD in the R + D-group (+4.1% at 1 year and +4.7% at 2 years, P < 0.0001) and in the R-group (+2.9% at 1 year and +2.8% at 2 years, P < 0.001), but the difference between the groups did not reach a significant level. Vitamin D status at randomization did not affect the subsequent BMD response in coadministration of alfacalcidol with raloxifene. Supplementation with alfacalcidol to raloxifene therapy demonstrates a greater bone-sparing effect by suppressing the secondary increment of serum PTH than when raloxifene is used alone.


Asunto(s)
Pueblo Asiatico , Huesos/patología , Suplementos Dietéticos , Hidroxicolecalciferoles/uso terapéutico , Tratamientos Conservadores del Órgano , Osteoporosis Posmenopáusica/tratamiento farmacológico , Clorhidrato de Raloxifeno/uso terapéutico , Anciano , Anciano de 80 o más Años , Densidad Ósea/efectos de los fármacos , Conservadores de la Densidad Ósea/farmacología , Conservadores de la Densidad Ósea/uso terapéutico , Huesos/efectos de los fármacos , Huesos/fisiopatología , Calcio/sangre , Colágeno Tipo I/orina , Demografía , Quimioterapia Combinada , Femenino , Cadera/fisiopatología , Humanos , Hidroxicolecalciferoles/farmacología , Japón , Vértebras Lumbares/efectos de los fármacos , Vértebras Lumbares/fisiopatología , Persona de Mediana Edad , Osteoporosis Posmenopáusica/sangre , Osteoporosis Posmenopáusica/fisiopatología , Osteoporosis Posmenopáusica/orina , Hormona Paratiroidea/sangre , Péptidos/orina , Posmenopausia/efectos de los fármacos , Clorhidrato de Raloxifeno/farmacología
10.
J Physiol Sci ; 61(6): 525-35, 2011 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-21909988

RESUMEN

Supra-physiological levels of vitamin D induce skeletal muscle atrophy, which may be particularly detrimental in already sarcopaenic elderly. Neither the cause nor whether the atrophy is fibre type specific are known. To obtain supraphysiological levels of circulating vitamin D (1,25(OH)(2)D(3)) 27.5-month-old female Fischer(344) × Brown Norway F1 rats were orally treated for 6 weeks with vehicle or the vitamin D analogue alfacalcidol. Alfacalcidol treatment induced a 22% decrease in body mass and 17% muscle atrophy. Fibre atrophy was restricted to type IIb fibres in the low-oxidative part of the gastrocnemius medialis only (-22%; P < 0.05). There was a concomitant 1.6-fold increase in mRNA expression of the ubiquitin ligase MuRF-1 (P < 0.001), whereas those of insulin-like growth factor 1 and myostatin were not affected. Circulating IL-6 was unaltered, but leptin and adiponectin were decreased (-39%) and increased (64%), respectively. The treated rats also exhibited a reduced food intake. In conclusion, supraphysiological levels of circulating 1,25(OH)(2)D(3) cause preferential atrophy of type IIb fibres, which is associated with an increased expression of MuRF-1 without evidence of systemic inflammation. The atrophy and loss of body mass in the presence of supra-physiological levels of vitamin D are primarily due to a reduced food intake.


Asunto(s)
Hidroxicolecalciferoles/farmacología , Péptidos y Proteínas de Señalización Intercelular/metabolismo , Interleucina-6/sangre , Músculo Esquelético/efectos de los fármacos , Músculo Esquelético/metabolismo , Vitamina D/análogos & derivados , Vitamina D/sangre , Adiponectina/sangre , Animales , Índice de Masa Corporal , Suplementos Dietéticos , Ingestión de Alimentos/efectos de los fármacos , Femenino , Inflamación/sangre , Factor I del Crecimiento Similar a la Insulina/metabolismo , Péptidos y Proteínas de Señalización Intercelular/sangre , Leptina/sangre , Fibras Musculares Esqueléticas/efectos de los fármacos , Fibras Musculares Esqueléticas/metabolismo , Proteínas Musculares/biosíntesis , Proteínas Musculares/genética , Proteínas Musculares/metabolismo , Atrofia Muscular/sangre , Atrofia Muscular/genética , Atrofia Muscular/metabolismo , Miostatina/metabolismo , Tamaño de los Órganos/efectos de los fármacos , ARN Mensajero/biosíntesis , ARN Mensajero/genética , Ratas , Proteínas de Motivos Tripartitos , Ubiquitina-Proteína Ligasas/biosíntesis , Ubiquitina-Proteína Ligasas/genética , Ubiquitina-Proteína Ligasas/metabolismo , Vitamina D/farmacología
11.
BMC Biotechnol ; 11: 33, 2011 Apr 07.
Artículo en Inglés | MEDLINE | ID: mdl-21473770

RESUMEN

BACKGROUND: Analogues of vitamin D3 are extensively used in the treatment of various illnesses, such as osteoporosis, inflammatory skin diseases, and cancer. Functional testing of new vitamin D3 analogues and formulations for improved systemic and topical administration is supported by sensitive screening methods that allow a comparative evaluation of drug properties. As a new tool in functional screening of vitamin D3 analogues, we describe a genomically integratable sensor for sensitive drug detection. This system facilitates assessment of the pharmacokinetic and pharmadynamic properties of vitamin D3 analogues. The tri-cistronic genetic sensor encodes a drug-sensoring protein, a reporter protein expressed from an activated sensor-responsive promoter, and a resistance marker. RESULTS: The three expression cassettes, inserted in a head-to-tail orientation in a Sleeping Beauty DNA transposon vector, are efficiently inserted as a single genetic entity into the genome of cells of interest in a reaction catalyzed by the hyperactive SB100X transposase. The applicability of the sensor for screening purposes is demonstrated by the functional comparison of potent synthetic analogues of vitamin D3 designed for the treatment of psoriasis and cancer. In clones of human keratinocytes carrying from a single to numerous insertions of the vitamin D3 sensor, a sensitive sensor read-out is detected upon exposure to even low concentrations of vitamin D3 analogues. In comparative studies, the sensor unveils superior potency of new candidate drugs in comparison with analogues that are currently in clinical use. CONCLUSIONS: Our findings demonstrate the use of the genetic sensor as a tool in first-line evaluation of new vitamin D3 analogues and pave the way for new types of drug delivery studies in sensor-transgenic animals.


Asunto(s)
Colecalciferol/farmacología , Elementos Transponibles de ADN/genética , Queratinocitos/efectos de los fármacos , Elementos de Respuesta/genética , Animales , Calcitriol/análogos & derivados , Calcitriol/farmacología , Línea Celular , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Colecalciferol/análogos & derivados , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos/métodos , Vectores Genéticos/genética , Proteínas Fluorescentes Verdes/genética , Proteínas Fluorescentes Verdes/metabolismo , Humanos , Hidroxicolecalciferoles/farmacología , Queratinocitos/citología , Queratinocitos/metabolismo , Microscopía Fluorescente , Mutagénesis Insercional , Receptores X Retinoide/genética , Transfección , Transposasas/genética , Transposasas/metabolismo , Proteína de Unión a Vitamina D/genética
12.
Nihon Ronen Igakkai Zasshi ; 48(6): 691-8, 2011.
Artículo en Japonés | MEDLINE | ID: mdl-22322042

RESUMEN

AIM: A characteristic condition of pre-frail elderly people is decreased mobility, which is associated with vitamin D levels and renal function. The aim of this study was to examine the association between physical fitness improvement and vitamin D levels, vitamin D supplements, and renal function in pre-frail elderly people. METHODS: We conducted a longitudinal study in 2 towns from June 2006 to December 2009. Subjects consisted of 177 community-dwelling pre-frail elderly people aged 65 years and over (mean±standard deviation [SD]: 76.4±5.5 yrs) who attended a nursing care prevention program for 3 months. An interview was conducted based on a questionnaire. Serum levels of intact parathyroid hormone (iPTH), 25-hydroxyvitamin D(25(OH)D), 1,25-dihydroxyvitamin D (1,25(OH)(2)D), creatinine, and calcium were measured. eGFR (ml/min/1.73 m(2)) was calculated using a new formula. Alfacalcidol 1 µg/day was administered to subjects for 3 months, and we assumed that the elderly who took vitamin D (VD) of more than 80% of the recommended daily allowance to be the VD group. Walking ability, balance, and muscle strength physical fitness tests were performed. RESULTS: The prevalence of eGFR <60.0 ml/min/1.73 m(2) was about 24.3%, and that of 25(OH)D <75 nmol/L was 86.4%. Pre-eGFR level and vitamin D supplementation with FR, pre-eGFR and pre 25(OH)D ≥45 nmol/L were associated with improvement in the timed up and go (TUG) test, pre-25(OH)D level (<50 nmol/L, ≥50 nmol/L) was associated with the tandem stance test, pre 25(OH)D level (<67.5 nmol/L, ≥67.5 nmol/L) was associated with the alternate step and 5 chair sit-to-stands tests, and post 1,25(OH)(2)D (<44 pg/ml, ≥44 pg/ml) was associated with the tandem walk tests. CONCLUSIONS: These results suggest that the assessment of renal function and maintenance of appropriate vitamin D levels are important for the independent living of pre-frail elderly people. Ideally, a 25(OH)D level greater than 67.5 nmol/L is preferable.


Asunto(s)
Hidroxicolecalciferoles/farmacología , Riñón/fisiología , Aptitud Física/fisiología , Anciano , Anciano de 80 o más Años , Femenino , Tasa de Filtración Glomerular , Humanos , Masculino , Vitamina D/sangre
13.
J Steroid Biochem Mol Biol ; 121(1-2): 261-4, 2010 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-20298784

RESUMEN

Eldecalcitol [ED-71, 2beta-(3-hydroxypropyloxy)-1,25-dihydroxyvitamin D3] increases lumbar and hip bone mineral density (BMD) in a dose-dependent manner in osteoporotic patients with vitamin D supplementation. However, there has been no head-to-head comparison of the effects of eldecalcitol with alfacalcidol on bone and calcium metabolism in human subjects. Therefore, a randomized open-label clinical trial was conducted to compare the effect of eldecalcitol on bone turnover markers and calcium metabolism in 59 Japanese postmenopausal women. Subjects were randomly assigned to receive 1.0 microg alfacalcidol, 0.5 or 1.0 microg eldecalcitol once a day for 12 weeks. There was almost no increase in serum calcium (Ca) throughout the study period. Eldecalcitol from 0.5 to 1.0 microg increased daily urinary Ca excretion in a dose-dependent manner, and 1.0 microg eldecalcitol increased urinary Ca to a similar extent to 1.0 microg alfacalcidol. Both 0.5 and 1.0 microg eldecalcitol suppressed urinary NTX stronger than 1.0 microg alfacalcidol (-6, -30 and -35% in 1.0 microg alfacalcidol, 0.5 and 1.0 microg eldecalcitol-treated groups, respectively, at 12 weeks). In contrast, changes in serum BALP were similar among the three groups (-22, -22 and -29% in 1.0 microg alfacalcidol, 0.5 and 1.0 microg eldecalcitol-treated groups, respectively, at 12 weeks). These results demonstrate that 0.5-1.0 microg eldecalcitol can effectively inhibit bone resorption stronger than alfacalcidol with a similar effect on bone formation and a comparable effect on urinary Ca excretion, and suggest that eldecalcitol may have a better osteoprotective effect than alfacalcidol.


Asunto(s)
Huesos/metabolismo , Calcio/metabolismo , Hidroxicolecalciferoles/farmacología , Vitamina D/análogos & derivados , Anciano , Fosfatasa Alcalina/sangre , Biomarcadores/metabolismo , Resorción Ósea , Colágeno Tipo I/sangre , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Persona de Mediana Edad , Modelos Biológicos , Péptidos/sangre , Posmenopausia , Vitamina D/farmacología
14.
Poult Sci ; 88(2): 323-9, 2009 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-19151347

RESUMEN

This experiment was conducted to investigate the effects of 1alpha-hydroxycholecalciferol (1alpha-OH D3) on the growth performance, tibia and plasma parameters, nutrient utilization, meat quality of the breast and thigh, and type IIb sodium phosphate cotranspoter gene expression of broilers. A total of 96 males of 1-d-old Arbor Acres broilers were randomly assigned to 8 cages of 12 birds each. Two dietary treatments were applied to 4 cages each. Diet 1 was prepared as the basal diet (nonphytate phosphorus, 0.21%), whereas diet 2 was the basal diet supplemented with 5 microg/kg of 1alpha-OH D3. Results showed that supplementation of the basal diet with 1alpha-OH D3 increased growth performance, tibia ash and strength, plasma inorganic phosphate concentration, utilization of total phosphorus and nonphytate phosphorus, lightness and yellowness of the breast and thigh meat, and intestinal type IIb sodium phosphate cotranspoter mRNA expression, whereas it decreased the shear force and water-holding capacity of the thigh meat. These data suggest that the addition of 1alpha-OH D3 might improve growth performance, tibia development, and meat quality in 1- to 21-d-old broilers by increasing the absorption and retention of phosphorus.


Asunto(s)
Pollos/crecimiento & desarrollo , Pollos/metabolismo , Dieta/veterinaria , Regulación de la Expresión Génica/efectos de los fármacos , Hidroxicolecalciferoles/farmacología , Carne/normas , Tibia/efectos de los fármacos , Fenómenos Fisiológicos Nutricionales de los Animales/efectos de los fármacos , Animales , Pollos/sangre , Suplementos Dietéticos , Hidroxicolecalciferoles/administración & dosificación , Masculino , Distribución Aleatoria , Proteínas Cotransportadoras de Sodio-Fosfato de Tipo IIb/genética
15.
Artículo en Inglés | MEDLINE | ID: mdl-18799859

RESUMEN

The present study compared the bone anabolic effects of graded doses of alfacalcidol in proximal femurs (hematopoietic, red marrow skeletal site) and distal tibiae (fatty, yellow marrow skeletal site). One group of 8.5-month-old female Sprague-Dawley rats were killed at baseline and 4 groups were treated 5 days on/2 days off/week for 12 weeks with 0, 0.025, 0.05 and 0.1 microg alfacalcidol/kg by oral gavage. The proximal femur, bone site with hematopoietic marrow, as well as the distal tibia bone site with fatty marrow, were processed undecalcified for quantitative bone histomorphometry. In the red marrow site of the proximal femoral metaphysis (PFM), 0.1 microg alfacalcidol/kg induced increased cancellous bone mass, improved architecture (decreased trabecular separation, increased connectivity), and stimulated local bone formation of bone 'boutons' (localized bone formation) on trabecular surfaces. There was an imbalance in bone resorption and formation, in which the magnitude of depressed bone resorption greater than depressed bone formation resulted in a positive bone balance. In addition, bone 'bouton' formation contributed to an increase in bone mass. In contrast, the yellow marrow site of the distal tibial metaphysis (DTM), the 0.1 microg alfacalcidol/kg dose induced a non-significant increased cancellous bone mass. The treatment decreased bone resorption equal to the magnitude of decreased bone formation. No bone 'bouton' formation was observed. These findings indicate that the highest dose of 0.1 microg alfacalcidol/kg for 12 weeks increased bone mass (anabolic effect) at the skeletal site with hematopoietic marrow of the proximal femoral metaphysis, but the increased bone mass was greatly attenuated at the fatty marrow site of the distal tibial metaphysis. In addition, the magnitude of the bone gain induced by alfacalcidol treatment in red marrow cancellous bone sites of the proximal femoral metaphysis was half that of the lumbar vertebral body. The latter data were from a previous report from the same animal and protocol. These findings indicated that alfacalcidol as an osteoporosis therapy is less efficacious as a positive bone balance agent that increased trabecular bone mass in a non-vertebral skeletal site where bone marrow is less hematopoietic.


Asunto(s)
Conservadores de la Densidad Ósea/farmacología , Médula Ósea/efectos de los fármacos , Fémur/efectos de los fármacos , Hidroxicolecalciferoles/farmacología , Tibia/efectos de los fármacos , Animales , Conservadores de la Densidad Ósea/administración & dosificación , Remodelación Ósea/efectos de los fármacos , Resorción Ósea , Calcio/sangre , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Femenino , Fémur/fisiología , Hematopoyesis/efectos de los fármacos , Hidroxicolecalciferoles/administración & dosificación , Tamaño de los Órganos/efectos de los fármacos , Osteogénesis/efectos de los fármacos , Fósforo/sangre , Ratas , Ratas Sprague-Dawley , Tibia/fisiología
16.
Calcif Tissue Int ; 82(2): 127-36, 2008 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-18175034

RESUMEN

PURPOSE: To investigate the skeletal effects of alfacalcidol alone or in combination with exercise in intact adult female rats. METHODS: Seventy-four 8.5-month-old rats were orally administered 0, 0.005, 0.025, 0.05 or 0.1 microg/kg of alfacalcidol for 12 weeks, alone or in combination with exercise. Cancellous bone histomorphometric measurements were performed on the second lumbar vertebra. RESULTS: At 0.05 and 0.1 microg/kg, alfacalcidol caused a significant increase in cancellous bone volume, accompanied by an increase in trabecular architecture. Percent eroded surface, bone resorption and formation were suppressed by alfacalcidol treatment. However, mineral apposition rate was significantly increased, indicating osteoblast activity was increased. A positive balance between bone formation and resorption was observed in the rats treated with the highest dose of alfacalcidol. Alfacalcidol induced a unique bone formation site ("bouton") on the cancellous surface. These boutons connected adjacent trabeculae and increased trabecular thickness. They exhibited both smooth and scalloped cement lines, suggesting that they were formed by minimodeling- and remodeling-based bone formation. Furthermore, alfacalcidol at 0.1 microg/kg increased periosteal bone formation of the lumbar transverse processes. Bipedal stance exercise alone did not have an effect on bone balance and bone turnover. There were no interactions between alfacalcidol and bipedal stance exercise except for a decrease in bone resorption. CONCLUSION: Alfacalcidol exhibited both anti-catabolic and anabolic effects on bone in intact female rats. The effect of combined treatment with alfacalcidol and bipedal stance exercise was no better than that of alfacalcidol alone.


Asunto(s)
Conservadores de la Densidad Ósea/farmacología , Hidroxicolecalciferoles/farmacología , Vértebras Lumbares/efectos de los fármacos , Osteogénesis/efectos de los fármacos , Periostio/efectos de los fármacos , Condicionamiento Físico Animal , Administración Oral , Envejecimiento/fisiología , Animales , Resorción Ósea/tratamiento farmacológico , Resorción Ósea/patología , Resorción Ósea/prevención & control , Calcio/sangre , Relación Dosis-Respuesta a Droga , Femenino , Vértebras Lumbares/metabolismo , Vértebras Lumbares/patología , Osteoblastos/efectos de los fármacos , Osteoblastos/metabolismo , Osteoblastos/patología , Osteogénesis/fisiología , Periostio/metabolismo , Periostio/patología , Fósforo/sangre , Condicionamiento Físico Animal/métodos , Ratas , Ratas Sprague-Dawley
17.
J Nutr Sci Vitaminol (Tokyo) ; 53(3): 191-7, 2007 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-17874822

RESUMEN

The beneficial effects of alfacalcidol (ALF) on bone mass, bone formation, and bone resorption have been established in ovariectomized rats. Our previous studies showed that high-dose glucocorticoid (GC) administration (methylprednisolone sodium succinate, 5.0 mg/kg, s.c., 3 times a week) for 4 wk induced cancellous osteopenia without significantly affecting cortical bone mass in Sprague-Dawley rats, and that high-dose GC administration for 8 wk also resulted in cortical osteopenia. The purpose of the present study was to examine the effects of ALF on cancellous and cortical bone mass in GC-treated rats. Forty female Sprague-Dawley rats, 3 mo of age, were randomized by the stratified weight method into four groups of 10 rats each, as follows: age-matched control group (CON); 8-wk GC administration with administration of vehicle during the latter 4 wk of treatment (GC group); 8-wk GC administration with administration of a low dose of ALF (0.08 Ag/kg) during the latter 4 wk of treatment (low-dose ALF group); 8-wk administration of GC with administration of a high dose ofALF (0.16 microg/kg) during the latter 4 wk of treatment (high-dose ALF group). The GC (methylprednisolone sodium succinate, 5.0 mg/kg) was administered subcutaneously 3 times a week, and ALF was administered orally 5 times a week. At the end of the experiment, static and dynamic bone histomorphometric analyses were performed on cancellous bone of the proximal tibial metaphysis and cortical bone of the tibial diaphysis. Eight-week GC administration resulted in loss of the cancellous bone volume/total tissue volume (BV/TV) and percent cortical area (Ct Ar) as a result of decreased trabecular bone formation, increased trabecular and endocortical bone resorption, and decreased periosteal bone formation. Low-dose ALF restored the cancellous BV/TV by mildly suppressing bone resorption and restoring bone formation, whereas high-dose ALF increased it beyond the value observed in the age-matched controls by strongly suppressing bone resorption and markedly increasing bone formation. Both low- and high-dose ALF prevented the GC-induced reduction of the percent Ct Ar by increasing periosteal bone formation and suppressing endocortical bone resorption. The effects of ALF on cancellous bone mass, bone formation, and bone resorption were all dose-dependent. The present study showed the beneficial effects of ALF on cancellous and cortical bone mass in GC-treated rats.


Asunto(s)
Conservadores de la Densidad Ósea/farmacología , Densidad Ósea/efectos de los fármacos , Hidroxicolecalciferoles/farmacología , Osteoporosis/prevención & control , Análisis de Varianza , Animales , Peso Corporal/efectos de los fármacos , Resorción Ósea/prevención & control , Calcio/sangre , Creatinina/sangre , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Femenino , Fémur/efectos de los fármacos , Glucocorticoides , Hemisuccinato de Metilprednisolona/administración & dosificación , Osteoporosis/inducido químicamente , Osteoporosis/patología , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley , Tibia/efectos de los fármacos
18.
Calcif Tissue Int ; 78(3): 152-61, 2006 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-16525749

RESUMEN

The purpose of this study was to assess whether a nutritional supply of calcium (Ca) could be substituted for alfacalcidol (ALF) administration in preventing bone loss due to estrogen deficiency. Female Wistar-Imamichi rats (8 months old) were ovariectomized (OVX) or sham-operated. OVX rats received ALF administration (0.025, 0.5, or 0.1 microg/kg, p.o., 5 times a week) with standard rodent chow [Ca 1.2%, phosphorus (P) 1.04%], a Ca-enriched diet containing 2%, 4%, or 6% Ca (Ca/P ratio of 2, 4, and 6, respectively), or a Ca/P-enriched diet (Ca/P ratio of 1.2). After 12 weeks of treatment, all rats were killed to harvest the spine, serum, and urine samples. Neither the ALF treatment nor the Ca supplement caused hypercalcemia. In the spine, ALF prevented decreases in bone mineral density (BMD) and compressive strength of lumbar spine induced by OVX. Micro-computed tomographic analysis confirmed that ALF significantly improved the trabecular bone pattern factor and the structure model index and suppressed bone destruction. In contrast, of particular interest, high-dose Ca administration did not have marked effects on bone fragility. Also, when both Ca and P were administered in high doses, BMD and mechanical strength decreased dose-dependently, urinary P excretion significantly increased, and serum parathyroid hormone level increased. Together, it is difficult to adjust the Ca supply through diet alone without disrupting the balance between serum Ca and P levels. Consequently, we conclude that ALF is beneficial for the treatment of osteoporosis, which is not achieved by the use of a Ca supplement.


Asunto(s)
Conservadores de la Densidad Ósea/farmacología , Densidad Ósea/fisiología , Calcio de la Dieta/administración & dosificación , Hidroxicolecalciferoles/farmacología , Osteoporosis/tratamiento farmacológico , Aminoácidos/orina , Animales , Nitrógeno de la Urea Sanguínea , Densidad Ósea/efectos de los fármacos , Calcio/sangre , Calcio/orina , Calcio de la Dieta/uso terapéutico , Fuerza Compresiva , Creatinina/análisis , Creatinina/orina , Relación Dosis-Respuesta a Droga , Ensayo de Inmunoadsorción Enzimática , Femenino , Ovariectomía , Hormona Paratiroidea/sangre , Fósforo/sangre , Fósforo/orina , Ratas , Ratas Wistar , Tomografía Computarizada por Rayos X
19.
J Nutr Sci Vitaminol (Tokyo) ; 52(6): 393-401, 2006 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-17330501

RESUMEN

The purpose of the present study was to compare the effects of risedronate (RIS) and alfacalcidol (ALF) on the cortical and cancellous bone mass and mechanical properties in ovariectomized rats in a head-to-head fashion. Forty female Sprague-Dawley rats, 7 mo of age, were randomized into six groups: the sham-operated control (Sham) group, and five ovariectomized groups: treated with vehicle, RIS (0.1, 1.0, or 2.5 mg/kg, p.o., daily), and ALF (0.5 microg/kg, p.o., daily). At the end of the 8-wk experimental period, bone histomorphometric analyses of the cancellous bone of the proximal tibial metaphysis and cortical bone of the tibial disphysis was performed, and the mechanical properties of the bone were evaluated at the femoral distal metaphysis (FDM) and femoral diaphysis (FD). RIS prevented the decrease in the cancellous bone volume/total tissue volume (BV/TV) noted in ovariectomized rats in a dose-dependent manner, by suppressing increases in cancellous bone formation and resorption, without any apparent effect on the Ct Ar or maximum load of the FDM or FD. On the other hand, ALF increased the cancellous BV/TV, Ct Ar, and maximum load of the FDM or FD, by mildly decreasing cancellous bone formation and resorption, increasing periosteal and endocortical bone formation, and preventing an increase in endocortical bone resorption. Thus, the present study clearly showed that RIS and ALF had differential effects on the cortical and cancellous bone mass and mechanical properties in ovariectomized rats.


Asunto(s)
Conservadores de la Densidad Ósea/farmacología , Densidad Ósea/efectos de los fármacos , Resorción Ósea/prevención & control , Ácido Etidrónico/análogos & derivados , Hidroxicolecalciferoles/farmacología , Análisis de Varianza , Animales , Peso Corporal/efectos de los fármacos , Calcio/sangre , Relación Dosis-Respuesta a Droga , Ácido Etidrónico/farmacología , Femenino , Fémur/efectos de los fármacos , Ovariectomía , Fósforo/sangre , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley , Ácido Risedrónico , Estrés Mecánico , Tibia/efectos de los fármacos
20.
Poult Sci ; 84(10): 1616-28, 2005 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16335132

RESUMEN

Supplemental 1alpha-hydroxycholecalciferol (1alpha-OHD3) has been shown to have qualitatively similar and quantitatively additive effects to exogenous phytase. Two experiments were conducted from 0 to 35 d in floor pens to determine the additive effect of phytase and 1alpha-OHD3 when supplemented to Ca- and P-deficient diets. In both experiments, at least 4 replicates per treatment (50 chicks per replicate) were used. Corn-soybean-meal-and soybean-oil-based diets were fed and birds were raised in a house impervious to ultraviolet light. During the starter phase (ST), from 0 to 18 d, chicks were fed a 23% CP diet containing 0.60% Ca and 0.47% total P (tP). During the grower/finisher phase (GF), from 19 to 35 d, birds were fed a 19% CP diet containing 0.30% Ca and 0.37% tP. A combination of 1,000 phytase units/kg of Natuphos phytase and 5 microg/kg of 1alpha-OHD3 (P+1A) was supplemented to some of the feed during the ST and GF. Diets containing adequate Ca and P were also fed during the ST (0.90% Ca, 0.68% tP) and GF (0.80% Ca, 0.67% tP). Performance characteristics and the incidence of rickets and tibial dyschondroplasia were measured at 18 and 35 d. In experiment 1, unsupplemented chicks performed well but had considerable leg problems. Chicks fed P+1A during the ST or GF did not perform as well as birds fed P+1A throughout. Birds fed P+1A throughout performed as well birds fed the adequate diets without any indication of leg problems. In experiment 2, unsupplemented birds performed similarly to unsupplemented birds in experiment 1. However, chicks fed the supplements or the control diets did not perform as well or accumulate as much bone ash as birds in experiment 1, although the diets were formulated identically in both experiments. Diets with as little as 0.30% Ca and 0.37% tP appear to be adequate for broilers older than 18 d if supplemented with the correct amounts of phytase and 1alpha-OHD3. However, there are unknown variables that may limit the potential of broilers in terms of bone mineralization and bone pathology, even when adequate diets are fed.


Asunto(s)
6-Fitasa/farmacología , Pollos/crecimiento & desarrollo , Suplementos Dietéticos , Hidroxicolecalciferoles/farmacología , 6-Fitasa/administración & dosificación , Alimentación Animal , Animales , Calcio/metabolismo , Dieta , Femenino , Hidroxicolecalciferoles/administración & dosificación , Masculino , Fósforo/metabolismo , Aumento de Peso/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA